Crypto derivatives should be banks’ ‘gateway drug’ to spot: B2C2

- By Joe Parsons
- @Joe_Parsons416
- 09 Jun 2022

Tweet
Facebook
LinkedIn
Save this article
Send to
Print this page

Cash-settled crypto derivatives should not be the end goal for banks, according to one of the founders of crypto market-maker B2C2; rather they should be a “gateway drug” to trade the physical product, for which liquidity conditions have improved significantly.

Banks including Goldman Sachs and Nomura have been among the traditional finance world’s first movers in trading bitcoin futures and non-deliverable forwards, while several other futures commission merchants (FCMs) have offered clearing

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact customer services - www.fx-markets.com/static/contact-us, or view our subscription options here: https://subscriptions.fx-markets.com/subscribe

You are currently unable to print this content. Please contact customer services - www.fx-markets.com/static/contact-us to find out more.

You are currently unable to copy this content. Please contact info@fx-markets.com to find out more.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@fx-markets.com

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@fx-markets.com